Doxylamine and melatonin in treatment of sleep disruption in gynecological practice

Burchakov, D I

doi:10.17116/jnevro20181184267

Cited by 4 publications

(2 citation statements)

References 28 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…В рандомизированном двой ном слепом исследовании с участием 338 пациентов при сравнении выраженности снотворного эффекта и безопасности доксиламина и золпидема отмечено, что эффективность и переносимость препаратов была сопоставимая, а побочные эффекты в группе пациентов, принимавших доксиламин, встречались несколько реже [108]. Эффективность и безопасность доксиламина показана у пациентов разного профиля как с неврологическими [108][109][110], так и с соматическими заболеваниями [105,[111][112][113][114].…”

Section: Neuropsychiatric Disordersunclassified

Insomnia: definition, prevalence, health risks and therapy approaches

Пизова

2023

Medicinskij sovet

View full text Add to dashboard Cite

Insomnia is a common disorder among the general population, which has a chronic course and a heavy burden on patients and the health care system. Epidemiological papers on sleep disorders show that a large number of people complain of sleep disorders. Today, there are several classifications and definitions for sleep disorders, and first of all for insomnia. Insufficient sleep can contribute to the occurrence of rapid fatigue during the daytime, reduced activity, attention and efficiency. Studies have shown that long-term and severe sleep disorders can lead to and/or exacerbate various somatic, neurological and mental diseases. Insomnia can contribute to cognitive impairment. Although both non-pharmacological and pharmacological interventions are available, drugs are more often prescribed due to greater availability. Cognitive behavioural therapy for insomnia is recommended as the first line treatment for adults of any age. Pharmacological intervention may be offered, if cognitive behavioural therapy for insomnia is not enough effective or not available. At the same time, the pharmacotherapy for sleep disorders remains problematic despite a large number of sleeping pills. Sleeping agents that are widely used in medical practice both in terms of their mechanisms of action and final results such as their effect on sleep do not always contribute to the development of natural (or at least close to physiological) sleep. Benzodiazepines, benzodiazepine receptor agonists, antidepressants, antihistamines, antipsychotics, melatonin, and phytotherapeutic medicines can be used to treat insomnia.

show abstract

Section: Neuropsychiatric Disordersunclassified

Insomnia: definition, prevalence, health risks and therapy approaches

Пизова

2023

Medicinskij sovet

View full text Add to dashboard Cite

show abstract

“…An in vitro model verified that PKA-ERK1/2 can mediate the shift of ventricular choroid plexus clock and regulate circadian rhythm [15]. Melatonin [16] and melatonin receptor agonists [17] have been widely used in the treatment of perimenopausal sleep disorders, but their mode of action remains unknown. Studies have attempted to explore the relationship between melatonin and perimenopausal sleep disorders from the perspective of lipid peroxidation and antioxidants [18], but the peroxidation-oxidation defense mechanism has not been adequately clarified.…”

Section: Introductionmentioning

confidence: 99%

Melatonin Alleviates Perimenopausal Sleep Disorders by Regulating the Expression of MTNR1A and Hormone Level: A Retrospective Study

Chen¹,

Zhang²,

Zhang³

2023

Clin. Exp. Obstet. Gynecol.

View full text Add to dashboard Cite

Background: Sleep disorder, frequently observed among perimenopausal women, decreases quality of life. Melatonin is reported to ameliorate circadian imbalances and thus can be employed as a treatment for perimenopausal sleep disorder patients. We attempted to clarify whether and how melatonin affects perimenopausal sleep disorders. Methods: Study patients consisted of 120 perimenopausal women divided into 3 groups: (i) perimenopausal women without sleep disorder (n = 60); (ii) those with sleep disorder but without melatonin treatment (n = 30); and (iii) those with sleep disorder with melatonin treatment (n = 30). During the period March 2019 to December 2019, the following data was collected and analyzed: Pittsburgh Sleep Quality index (PSQI) score, sex hormones, melatonin, melatonin 1A receptor (MTNR1A), protein kinase A (PKA), extracellular signal-regulated kinase 1/2 (ERK1/2), phosphorylation-PKA (p-PKA), and p-ERK1/2 levels. We compared these data between the groups. Results: Melatonin administration showed the following in female patients with postmenopausal sleep disorder: (1) significantly decreased the PSQI scores, (2) up-regulated melatonin levels and MTNR1A protein expression, (3) promoted the phosphorylation pathway of the PKA-ERK1/2 pathway in peripheral blood, and (4) significantly improved follicle-stimulating hormone (FSH), luteinizing hormone (LH) and estradiol (E2) levels. Melatonin administration had no significant effect on progesterone (P), testosterone (T) or prolactin (PRL). Conclusions: Melatonin therapy alleviated perimenopausal sleep disorders. Up-regulation of MTNR1A expression and improvement of the hormone balance were also observed, which may the reason for the observed sleep-disorder-amelioration. Melatonin has the potential to be a useful option for perimenopausal sleep disorders.

show abstract

Melatonin and premenstrual syndrome

Кузнецова¹

2018

Ross. vestn. akush.-ginekol.

View full text Add to dashboard Cite

Doxylamine and melatonin in treatment of sleep disruption in gynecological practice

Cited by 4 publications

References 28 publications

Insomnia: definition, prevalence, health risks and therapy approaches

Insomnia: definition, prevalence, health risks and therapy approaches

Melatonin Alleviates Perimenopausal Sleep Disorders by Regulating the Expression of MTNR1A and Hormone Level: A Retrospective Study

Melatonin and premenstrual syndrome

Contact Info

Product

Resources

About